Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Leukemia, Myeloid, Accelerated Phase 7Leukemia 7Blast Crisis 6Neoplasms 5Multiple Myeloma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Sezary Syndrome 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Large Granular Lymphocytic 3

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × Dasatinib × Clear all
NCT06645886 2026-03-25

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Kumquat Biosciences Inc.

Phase 1 Active not recruiting
13 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡